8-K - Immix Biopharma, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Immix Biopharma completed enrollment in its BLA-enabling NEXICART-2 Phase 2 trial of NXC-201 for relapsed/refractory AL Amyloidosis, with topline results expected in Q3 2026.

Key Takeaways

1Enrollment complete for 40-patient NEXICART-2 trial (NCT06097832) per guidance.

2Topline results expected Q3 2026, followed by BLA submission and planned commercial launch.

3Onboarded Chief Medical Officer Richard Graydon, MD, PhD, with experience at Merck and Johnson & Johnson.

4NXC-201 has FDA Breakthrough Therapy, RMAT, and Orphan Drug designations.

5Positive interim readout reported at ASH 2025.

Current Report Details

Event Type

Regulation Fd

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

and Exhibit 99.1 attached hereto are furnished and shall not be deemed to be “filed” with the Securities and Exchange Commission for purposes of Section 18 of t

Regulation Fd

8.01

. Other Events. ** On March 30, 2026, the Company issued a press release announcing that the enrollment for its NEXICART-2 clinical trial of NXC-201 is complete

Other Event

9.01

Financial Statements and Exhibits.** (d) Exhibits. | Exhibit No. | | Description | |---|---|---| | 99.1 | | Press Release issued by Immix Biopharma, Inc., dated

Exhibits Only

Source Document

Executive & Director Changes

Richard Graydon, MD, PhD

Chief Medical Officer

Onboarded

Effective: 2026-03-30

Exhibits (2)

8-K

99.1

EX-99.1